Table 3 Bayesian network meta-analysis of recurrence for comparisons
Comparator | Effect Sizes(95% CrI), by Treatment | Probability of being ranked most recurrence (%, 95% CI) | Rank most recurrence | |||
|---|---|---|---|---|---|---|
Bevacizumab | MMC | 5-FU | β-RT | |||
Placebo | 0.38(0.18, 0.80)* | 0.12(0.06, 0.21)* | 0.41(0.12, 1.39) | 0.17(0.04, 0.69)* | 85.63 (0, 100) | 1 |
Bevacizumab | – | 0.31(0.13, 0.77)* | 1.1(0.28, 4.30) | 0.45(0.10, 2.12) | 1.44 (0, 0) | 3 |
MMC | – | – | 3.56(1.01, 12.29)* | 1.47(0.34, 6.21) | 0 (0, 0) | 5 |
5-FU | – | – | – | 0.41(0.07, 2.56) | 11.07 (0, 100) | 2 |
β-RT | – | – | – | – | 1.86 (0, 0) | 4 |